Opioids, pain management and the law

R. Scott Stayner, David J Copenhaver

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Approximately 100 million people suffer from chronic pain in the USA. Opioid medications are commonly prescribed to treat pain, but are becoming the most widely misused controlled substance nationally. Physicians who treat patients with chronic pain must be cognizant of the federal and state policies that govern the distribution of opioid medications as well as the current standards of medical practice for opioid prescribing. RECENT FINDINGS: The laws and policies regarding the standard medical practice for opioid prescribing are constantly subject to revision. The National Drug Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and Management Strategy initiative. Currently there is a Risk Evaluation and Management Strategy for Transmucosal Immediate-Release Fentanyl. Other resources, such as state-run prescription drug monitoring programs, are also available to many physicians. The level of participation in these programs by physicians and pharmacists varies by state, and funding for continuation of these programs is an ongoing issue. SUMMARY: The problems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical and social policy that protects society and access to appropriate care for those in pain. Federal and state laws are in evolution, and clinicians must remain aware of these changes as well as the issues behind them that will impact safe and appropriate care of patients in pain.

Original languageEnglish (US)
Pages (from-to)566-571
Number of pages6
JournalCurrent Opinion in Anaesthesiology
Volume25
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Pain Management
Opioid Analgesics
Prescription Drug Misuse
Pain
Risk Management
Physicians
Chronic Pain
Controlled Substances
Prescription Drugs
Drug Monitoring
Drug and Narcotic Control
Fentanyl
Public Policy
Pharmacists
Patient Care

Keywords

  • Controlled Substances Act
  • Drug Enforcement Agency
  • opioids
  • pain management
  • prescription drug monitoring program
  • Risk Evaluation and Management Strategy

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Opioids, pain management and the law. / Stayner, R. Scott; Copenhaver, David J.

In: Current Opinion in Anaesthesiology, Vol. 25, No. 5, 10.2012, p. 566-571.

Research output: Contribution to journalArticle

Stayner, R. Scott ; Copenhaver, David J. / Opioids, pain management and the law. In: Current Opinion in Anaesthesiology. 2012 ; Vol. 25, No. 5. pp. 566-571.
@article{c77f5609d6f24f7ea6c09fe17dbbcb91,
title = "Opioids, pain management and the law",
abstract = "PURPOSE OF REVIEW: Approximately 100 million people suffer from chronic pain in the USA. Opioid medications are commonly prescribed to treat pain, but are becoming the most widely misused controlled substance nationally. Physicians who treat patients with chronic pain must be cognizant of the federal and state policies that govern the distribution of opioid medications as well as the current standards of medical practice for opioid prescribing. RECENT FINDINGS: The laws and policies regarding the standard medical practice for opioid prescribing are constantly subject to revision. The National Drug Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and Management Strategy initiative. Currently there is a Risk Evaluation and Management Strategy for Transmucosal Immediate-Release Fentanyl. Other resources, such as state-run prescription drug monitoring programs, are also available to many physicians. The level of participation in these programs by physicians and pharmacists varies by state, and funding for continuation of these programs is an ongoing issue. SUMMARY: The problems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical and social policy that protects society and access to appropriate care for those in pain. Federal and state laws are in evolution, and clinicians must remain aware of these changes as well as the issues behind them that will impact safe and appropriate care of patients in pain.",
keywords = "Controlled Substances Act, Drug Enforcement Agency, opioids, pain management, prescription drug monitoring program, Risk Evaluation and Management Strategy",
author = "Stayner, {R. Scott} and Copenhaver, {David J}",
year = "2012",
month = "10",
doi = "10.1097/ACO.0b013e328357a24a",
language = "English (US)",
volume = "25",
pages = "566--571",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Opioids, pain management and the law

AU - Stayner, R. Scott

AU - Copenhaver, David J

PY - 2012/10

Y1 - 2012/10

N2 - PURPOSE OF REVIEW: Approximately 100 million people suffer from chronic pain in the USA. Opioid medications are commonly prescribed to treat pain, but are becoming the most widely misused controlled substance nationally. Physicians who treat patients with chronic pain must be cognizant of the federal and state policies that govern the distribution of opioid medications as well as the current standards of medical practice for opioid prescribing. RECENT FINDINGS: The laws and policies regarding the standard medical practice for opioid prescribing are constantly subject to revision. The National Drug Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and Management Strategy initiative. Currently there is a Risk Evaluation and Management Strategy for Transmucosal Immediate-Release Fentanyl. Other resources, such as state-run prescription drug monitoring programs, are also available to many physicians. The level of participation in these programs by physicians and pharmacists varies by state, and funding for continuation of these programs is an ongoing issue. SUMMARY: The problems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical and social policy that protects society and access to appropriate care for those in pain. Federal and state laws are in evolution, and clinicians must remain aware of these changes as well as the issues behind them that will impact safe and appropriate care of patients in pain.

AB - PURPOSE OF REVIEW: Approximately 100 million people suffer from chronic pain in the USA. Opioid medications are commonly prescribed to treat pain, but are becoming the most widely misused controlled substance nationally. Physicians who treat patients with chronic pain must be cognizant of the federal and state policies that govern the distribution of opioid medications as well as the current standards of medical practice for opioid prescribing. RECENT FINDINGS: The laws and policies regarding the standard medical practice for opioid prescribing are constantly subject to revision. The National Drug Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and Management Strategy initiative. Currently there is a Risk Evaluation and Management Strategy for Transmucosal Immediate-Release Fentanyl. Other resources, such as state-run prescription drug monitoring programs, are also available to many physicians. The level of participation in these programs by physicians and pharmacists varies by state, and funding for continuation of these programs is an ongoing issue. SUMMARY: The problems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical and social policy that protects society and access to appropriate care for those in pain. Federal and state laws are in evolution, and clinicians must remain aware of these changes as well as the issues behind them that will impact safe and appropriate care of patients in pain.

KW - Controlled Substances Act

KW - Drug Enforcement Agency

KW - opioids

KW - pain management

KW - prescription drug monitoring program

KW - Risk Evaluation and Management Strategy

UR - http://www.scopus.com/inward/record.url?scp=84866387586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866387586&partnerID=8YFLogxK

U2 - 10.1097/ACO.0b013e328357a24a

DO - 10.1097/ACO.0b013e328357a24a

M3 - Article

VL - 25

SP - 566

EP - 571

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 5

ER -